Takeda & AC Immune have entered into an exclusive, worldwide option & license agreement to develop ACI-24.060, currently under P-Ib/II (ABATE) study to assess its safety, tolerability, immunogenicity & PD effects for prodromal Alzheimer’s disease & Down syndrome
As per the agreement, AC Immune will obtain $100M upfront, an aggregate of up to ~$2.1B for development, commercial & sales-based milestones as well as option exercise fee, plus double-digit global net-sales based tiered royalties
Furthermore, AC Immune will conclude the ABATE study, while Takeda will fund and carry out all future clinical development, global regulatory activities & commercialization
Ref: Takeda | Image: Takeda
Related News:- AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
